Molecular Partners doses first patients in Phase 2 MP0317 combo trial for cholangiocarcinoma
MOLN•Longer-term timeline through 2028
Trial completion is targeted for 2028, setting a multi-year timeline for clinical readouts that could shape the program’s next steps.
Phase 2 cholangiocarcinoma trial begins dosing
Molecular Partners began dosing patients in a randomized Phase 2 trial of MP0317 with standard first-line chemoimmunotherapy in advanced cholangiocarcinoma.
Early trial progress shows enrollment advancing as planned, with patients receiving multiple treatment cycles.
No results yet; updates planned for 2026 and 2027
No results have been presented yet; a trial-in-progress update is scheduled for ESMO 2026, with a data update expected in 2027.
The study tests whether adding MP0317 can improve outcomes versus standard of care alone, aiming for deeper and longer-lasting responses.
